Strides Pharma Science (Strides) has announced that its step‐down thoroughly owned subsidiary, Strides Pharma Global Pte. Ltd, Singapore, has obtained popularity of Triamcinolone Acetonide Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA). The product is part of the area of interest and small volume
product portfolio with restricted competition inside the US marketplace.
According to IQVIA MAT records, the US market for Triamcinolone Acetonide Ointment USP, zero.05% is about US$ 15 Mn. The product could be manufactured on the agency’s flagship facility at Bangalore and will be marketed by way of Strides Pharma Inc. Inside the US marketplace.
The enterprise has 124 cumulative ANDA filings with USFDA of which 86 ANDAs had been accepted and 38 are pending approval.
Bazaarinformation team has many years of experience, covering the physical and future commodities markets with prominent commodity & equity trading advising which shines further with extensive network to get research from ground levels to generate proper reporting and movements. We are able to get evens out of odds in volatile markets and stockings. ...
